MedTrace Logo

Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis

NCT01767701 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2017-05-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether raltegravir is effective in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium- enhanced MRI.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Raltegravir

400mg twice daily for 3 months

Sponsors & Collaborators

Principal Investigators

  • Julian Gold, Prof · Queen Mary University of London

  • Gavin Giovannoni · Queen Mary University of London

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01767701 on ClinicalTrials.gov